News

Wednesday September 27, 2017

27 Sep 2017 – Destiny Pharma to push ahead with next-generation antibiotic after Â...

Following on from the Interim Results published on the 27 September, Destiny Pharma CEO Neil Clark was interviewed by Proactive Investors. Click on the link for the full video interview:

Wednesday September 27, 2017

27 Sep 2017 – Destiny Pharma announce interim results 27th September 2017

Destiny Pharma announced its maiden interim results for the six months ending 30 June 2017 today. The interim results news release can be found here. An accompanying audio version of the […]

Tuesday September 19, 2017

19 Sep 2017 – More support announced for new antibiotics

Over the last week or so we have seen the WHO’s Global Antibiotic R&D Partnership (GARDP) announce a €56 million fund to fight antibiotic resistance, the EU/industry’s DRIVE-AB recommend four antibiotic […]

Monday September 4, 2017

04 Sep 2017 – Framework Agreement with China Medical Systems

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF […]

Monday September 4, 2017

04 Sep 2017 – Admission and First Day of Dealings on AIM

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF […]

Friday September 1, 2017

01 Sep 2017 – Destiny Pharma plc publishes Supplementary AIM Admission Document

Destiny Pharma plc today published a Supplementary AIM Admission document in respect of the admission to trading on AIM of its entire ordinary share capital, which is expected to take […]